{
  "hash": "a07aacec8adf7db6aa1e2d9d4477e678",
  "result": {
    "markdown": "---\ntitle: \"\"\nexecute:   \n  freeze: auto  # re-render only when source changes\noutput: \n  rmarkdown::html_document:\n    highlight: pygments\n    number_sections: yes\n    self_contained: yes\n    toc: yes\n    toc_depth: 2\n    toc_float: yes\n---\n\n\n\n\n::: {.panel-tabset .nav-pills}\n\n\n\n\n::: {.cell}\n\n:::\n\n# Submitted statistical articles {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|   |                                                                                                                                                                                                                                                                                                            |\n|:--|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|43 |Erdmann, A., Beyersmann, J., **Rufibach, K.** (**2024+**). Oncology clinical trial design planning based on a multistate model that jointly models progression-free and overall survival endpoints. _Submitted_. [preprint](https://arxiv.org/abs/2301.10059) &#124;  [markdown](https://insightsengineering.github.io/simIDM/latest-tag/) &#124;  [github](https://github.com/insightsengineering/simIDM) &#124;  [R package on cran](http://cran.r-project.org/package=simIDM) &#124;  [linkedin](https://www.linkedin.com/posts/kasparrufibach_oncology-multistate-survivalanalysis-activity-7024352913275678720-f1p1?utm_source=share&utm_medium=member_desktop) &#124;|\n:::\n:::\n\n::: {.cell}\n\n:::\n\n# Articles in statistical journals {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |\n|:--|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|42 |**Rufibach, K.**, Beyersmann, J., Friede, T., Schmoor, C., Stegherr, R. (**2024**). Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): summary of findings and a roadmap for the future of safety analyses in clinical trials. _Trials_, to appear. [doi](https://www.researchsquare.com/article/rs-3997626/v1) &#124;  [preprint](http://arxiv.org/abs/2402.17692) &#124;                                                                                                                                                                                                                                                |\n|41 |**Rufibach, K.**, Wolbers, M., Devenport, J., Yung, G., Harbron, C., Bedding, A., Huang, Z., Lin, R., Pang, H., Sabanés Bové, D., Wang, J. (**2024+**). Implementation of statistical innovation in a pharmaceutical company. _Statistics in Biopharmaceutical Research_, to appear. [doi](https://doi.org/10.1080/19466315.2024.2327291) &#124;  [preprint](https://osf.io/huq26/) &#124;                                                                                                                                                                                                                                                        |\n|40 |Polito, L., Liang, Q., Pal, N., Mpofu, P., Sawas, A., Humblet, O. **Rufibach, K.**, Heinzmann, D. (**2024**). Applying the Estimand and Target Trial frameworks to external control analyses using observational data: a case study in the solid tumor setting. _Front. Pharmacol._, **15**:1223858.  [doi](https://doi.org/10.3389/fphar.2024.1223858) &#124;  [preprint](https://arxiv.org/abs/2208.06707) &#124;                                                                                                                                                                                                                               |\n|39 |**Rufibach, K.**, Grinsted, L., Li, J., Weber, H.-J., Zheng, C. Zhou, J. (**2023**). Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions. _Pharmaceutical Statistics_, **22**(4), 671-691.  [doi](https://doi.org/10.1002/pst.2300) &#124;  [preprint](https://arxiv.org/abs/2206.05216) &#124;  [markdown](https://oncoestimand.github.io/quantFU/quantFU.html) &#124;                                                                                                                                                                                                        |\n|38 |**Rufibach, K.**, Stegherr, R., Schmoor, C., Jehl, V., Allignol, A., Boeckenhoff, A., Dunger-Baldauf, C., Eisele, L., Künzel, T., Kupas, K., Leverkus, F., Trampisch, M., Zhao, Y., Friede, Beyersmann, J. (**2023**). Survival analysis for AdVerse events with VarYing follow-up times (SAVVY) -- comparison of adverse event risks in randomized controlled trials. _Statistics in Biopharmaceutical Research_, **15**(4), 767-780.  [doi](https://doi.org/10.1080/19466315.2022.2144944) &#124;  [preprint](https://arxiv.org/abs/2008.07881) &#124;  [markdown](https://numbersman77.github.io/savvy/code.html) &#124;  [podcast](https://theeffectivestatistician.com/the-analysis-of-adverse-events-done-right-savvy/) &#124; . The first two authors contributed equally.|\n|37 |Ionan, A.C., Paterniti, M., Mehrotra, D., Scott, J., Ratitch, B., Collins, S., Gomatam, S., Nie, L., **Rufibach, K.**, Bretz, F. (**2023**). Clinical and Statistical Perspectives on the Estimand Framework Implementation. _Statistics in Biopharmaceutical Research_, **15**(3), 554-559.  [doi](https://doi.org/10.1080/19466315.2022.2081601) &#124;                                                                                                                                                                                                                                                                                         |\n|36 |Rajeshwari, S., Barksdale, E., Marchenko, O., Jiang, Q., Ando, Y., Bloomquist, E., Coory, M., Crouse, M., Degtyarev, E., Framke, T., Freidlin, B., Gerber, D.E., Gwise, T., Josephson, F., Hess, L., Kluetz, P., Li, D., Mandrekar, S., Posch, M., Rantell, K., Ratitch, B., Raven, A., Roes, K., **Rufibach, K.**, Sarac, S.B., Simon, R., Singh, H., Theoret, M., Thomson, A., Zuber, E., Shen, Y.L., Pazdur, R. (**2023**). Cancer Clinical Trials Beyond Pandemic: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. _Statistics in Biopharmaceutical Research_, **15**(2), 444-449.  [doi](https://doi.org/10.1080/19466315.2022.2103181) &#124;|\n|35 |Collignon, O., Schiel, A., Burman, C.F., **Rufibach, K.**, Posch, M., Bretz, F. (**2022**). Estimands and Complex Innovative Designs. _Clinical Pharmacology \\& Therapeutics_, **112**(6), 118-1190.  [doi](https://doi.org/10.1002/cpt.2575) &#124;                                                                                                                                                                                                                                                                                                                                                                                              |\n|34 |Kunzmann, K, Grayling, M.J., Lee, K.M., Robertson, D.S., **Rufibach, K.**, Wason, J.M.S. (**2022**). Conditional Power and Friends: The Why and How of (Un)planned, Unblinded Sample Size Recalculations in Confirmatory Trials. _Stat. Med._, **41**(5), 877-890.  [doi](https://doi.org/10.1002/sim.9288) &#124;  [preprint](https://arxiv.org/abs/2010.06567) &#124;                                                                                                                                                                                                                                                                           |\n|33 |Manitz, J., Kan-Dobrosky, N., Buchner, H., Casadebaig, M.L., Haddad, V., Jie, F., Martin, E., Tang, R., Yung, G., Zhou, J., Stalbovskaya, V., Shentu, Y., **Rufibach, K.**, Mo, M., Dey, J., Degtyarev, E. (**2022**). Estimands for Overall Survival in Clinical Trials with Treatment Switching in Oncology. _Pharm. Stat._, **21**:150-162.  [doi](https://doi.org/10.1002/pst.2158) &#124;                                                                                                                                                                                                                                                    |\n|32 |Stegherr, R., Schmoor, C., Beyersmann, J., **Rufibach, K.**, Jehl, V., Brueckner, A., Eisele, L., Kuenzel, T., Kupas, K., Langer, F., Loos, A., Norenberg, C., Voss, F., Friede, T. (**2021**). Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Estimation of adverse event risks. _Trials_, **22**(1), 420.  [doi](https://doi.org/10.1186/s13063-021-05354-x) &#124;  [preprint](https://arxiv.org/abs/2008.07883) &#124;  [markdown](https://numbersman77.github.io/savvy/code.html) &#124;  [podcast](https://theeffectivestatistician.com/the-analysis-of-adverse-events-done-right-savvy/) &#124;                |\n|31 |Kunzmann, K, Grayling, M.J., Lee, K.M., Robertson, D.S., **Rufibach, K.**, Wason, J.M.S. (**2021**). A review of Bayesian perspectives on sample size derivation for confirmatory trials. _Am. Stat._, **75**(4), 424-432.  [doi](https://doi.org/10.1080/00031305.2021.1901782) &#124;  [preprint](https://arxiv.org/abs/2006.15715) &#124;  [github](https://github.com/kkmann/sample-size-calculation-under-uncertainty) &#124;  [shiny](https://mybinder.org/v2/gh/kkmann/sample-size-calculation-under-uncertainty/0.2.1?urlpath=shiny/apps/sample-size-calculation-under-uncertainty/) &#124;                                               |\n|30 |Bornkamp, B., **Rufibach, K.**, Lin, J., Liu, Y., Mehrotra, D., Roychoudhury, S., Schmidli, H., Shentu, Y., Wolbers, M. (**2021**). Principal Stratum Strategy: Potential Role in Drug Development. _Pharm. Stat._, **20**:737-751.  [doi](https://doi.org/10.1002/pst.2104) &#124;  [preprint](https://arxiv.org/abs/2008.05406) &#124;  [markdown](https://oncoestimand.github.io/princ_strat_drug_dev/princ_strat_example.html) &#124;                                                                                                                                                                                                         |\n|29 |Sun, S., Weber, J., Butler, E., **Rufibach, K.**, Roychoudhury, S. (**2021**). Estimands in Hematology Trials. _Pharm. Stat._, **20**:793-805.  [doi](https://doi.org/10.1002/pst.2108) &#124;  [preprint](https://arxiv.org/abs/2010.00957) &#124;                                                                                                                                                                                                                                                                                                                                                                                               |\n|28 |Stegherr, R., Beyersmann, J., Jehl, V., **Rufibach, K.**, Leverkus, F., Schmoor, C., Friede, T. (**2021**). Survival analysis for AdVerse events with VarYing follow-up times (SAVVY): Rationale and statistical concept of a meta-analytic study. _Biom. J._, **63**:650-670.  [doi](https://doi.org/10.1002/bimj.201900347) &#124;  [preprint](https://arxiv.org/abs/1912.00263) &#124;  [markdown](https://numbersman77.github.io/savvy/code.html) &#124;  [podcast](https://theeffectivestatistician.com/the-analysis-of-adverse-events-done-right-savvy/) &#124;                                                                             |\n|27 |Lawrence, R., Degtyarev, E., Griffiths, P., Trask, P., Lau, H., D'Alessio, D., Griebsch, I., Wallenstein, G., Cocks, K., **Rufibach, K.** (**2020**). What is an estimand and how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials. _J Patient Rep Outcomes_, **4**(68), NA.  [doi](https://doi.org/10.1186%2Fs41687-020-00218-5) &#124;                                                                                                                                                                                                                                     |\n|26 |Degtyarev, E., **Rufibach, K.**, Shentu, Y., Yung, G., Casey, M., Englert, S., Liu, F., Liu, Y., Sailer, O., Siegel, J., Sun, S., Tang, R. (**2020**). Assessing the impact of COVID-19 on the objective and analysis of oncology clinical trials - application of the estimand framework. _Statistics in Biopharmaceutical Research_, **12**(4), 427-437.  [doi](https://doi.org/10.1080/19466315.2020.1785543) &#124;  [preprint](https://arxiv.org/abs/2006.04480) &#124; . The first four authors contributed equally.                                                                                                                        |\n|25 |**Rufibach, K.**, Heinzmann, D., Monnet, A. (**2020**). Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure Proportion - with an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia. _Pharm. Stat._, **19**:44-58.  [doi](https://doi.org/10.1002/pst.1969) &#124;  [preprint](https://arxiv.org/abs/1901.01308) &#124;  [github](https://github.com/numbersman77/integratePhase2) &#124;                                                                                                                                                                                         |\n|24 |Beyer, U., Dejardin, D., Meller, M., **Rufibach, K.**, Burger, H.U. (**2019**). A multistate model for early decision making in oncology. _Biom. J._, **62**(3), 550-567.  [doi](http://dx.doi.org/10.1002/bimj.201800250) &#124;  [preprint](https://arxiv.org/abs/1808.07221) &#124;                                                                                                                                                                                                                                                                                                                                                            |\n|23 |Meller, M., Beyersmann, J., **Rufibach, K.** (**2019**). Joint modelling of progression-free and overall survival and computation of correlation measures. _Stat. Med._, **38**:4270-4289.  [doi](http://dx.doi.org/10.1002/sim.8295) &#124;  [preprint](https://arxiv.org/abs/1810.10722) &#124;                                                                                                                                                                                                                                                                                                                                                 |\n|22 |**Rufibach, K.** (**2019**). Treatment Effect Quantification for Time-to-event Endpoints - Estimands, Analysis Strategies, and beyond. _Pharm. Stat._, **18**:144-164.  [doi](http://dx.doi.org/10.1002/pst.1917) &#124;  [preprint](https://arxiv.org/abs/1711.07518) &#124;                                                                                                                                                                                                                                                                                                                                                                     |\n|21 |**Rufibach, K.**, Burger, H.U., Abt, M. (**2016**). Bayesian Predictive Power: Choice of Prior and some Recommendations for its Use as Probability of Success in Drug Development. _Pharm. Stat._, **15**:438-446.  [doi](http://dx.doi.org/10.1002/pst.1764) &#124;  [github](https://github.com/numbersman77/bpp.git) &#124;  [R package on cran](http://cran.r-project.org/package=bpp) &#124;                                                                                                                                                                                                                                                 |\n|20 |Asikanius, E., **Rufibach, K.**, Bahlo, J., Bieska, G., Burger, H.U. (**2016**). Comparison of design strategies for a three-arm clinical trial with time-to-event endpoint. _Biom. J._, **58**(6), 1295-1310.  [doi](http://dx.doi.org/10.1002/bimj.201500077) &#124;                                                                                                                                                                                                                                                                                                                                                                            |\n|19 |**Rufibach, K.**, Chen M., Ngyuen, H. (**2016**). Comparison of different clinical development plans for confirmatory subpopulation selection. _Contemp. Clin. Trials_, **47**:78-84.  [doi](http://dx.doi.org/10.1016/j.cct.2015.12.014) &#124;                                                                                                                                                                                                                                                                                                                                                                                                  |\n|18 |**Rufibach, K.**, Jordan, P., Abt, M. (**2016**). Sequentially Updating the Likelihood of Success of a Phase 3 Pivotal Time-To-Event Trial based on Interim Analyses or External Information. _J. Biopharm. Stat._, **26**(2), 191-201.  [doi](http://dx.doi.org/10.1080/10543406.2014.972508) &#124;  [R package on cran](http://cran.r-project.org/package=bpp) &#124;                                                                                                                                                                                                                                                                          |\n|17 |Dümbgen, L., **Rufibach, K.**, Schuhmacher, D. (**2014**). Maximum-Likelihood Estimation of a Log-Concave Density based on Censored Data. _Electron. J. Stat._, **8**:1405-1437.  [doi](http://projecteuclid.org/euclid.ejs/1408540292) &#124;  [preprint](https://arxiv.org/abs/1311.6403) &#124;  [R package on cran](http://cran.r-project.org/package=logconcens) &#124;                                                                                                                                                                                                                                                                      |\n|16 |Balabdaoui, F., Jankowski, H., **Rufibach, K.**, Pavlides, M. (**2013**). Asymptotics of the discrete log-concave maximum likelihood estimator and related applications. _J. R. Stat. Soc. Ser. B Stat. Methodol._, **75**(4), 769-790.  [doi](http://dx.doi.org/10.1111/rssb.12011) &#124;  [preprint](http://arxiv.org/abs/1107.3904) &#124;  [R package on cran](http://cran.r-project.org/package=logcondiscr) &#124;                                                                                                                                                                                                                         |\n|15 |**Rufibach, K.** (**2012**). A smooth ROC curve estimator based on log-concave density estimates. _Int. J. Biostat._, **8**(1), 1-29.  [doi](http://dx.doi.org/10.1515/1557-4679.1378) &#124;  [preprint](http://arxiv.org/abs/1103.1787) &#124;  [R package on cran](http://cran.r-project.org/package=logcondens) &#124;                                                                                                                                                                                                                                                                                                                        |\n|14 |**Rufibach, K.** (**2011**). Selection models with monotone weight functions in meta analysis. _Biom. J._, **53**(4), 689-704.  [doi](http://dx.doi.org/10.1002/bimj.201000240) &#124;  [preprint](http://arxiv.org/abs/1102.4434) &#124;  [R package on cran](http://cran.r-project.org/package=selectMeta) &#124;                                                                                                                                                                                                                                                                                                                               |\n|13 |Dümbgen, L., **Rufibach, K.** (**2011**). logcondens: Computations Related to Univariate Log-Concave Density Estimation. _Journal of Statistical Software_, **39**(6), 1-28.  [doi](http://www.jstatsoft.org/v39/i06) &#124;  [R package on cran](http://cran.r-project.org/package=logcondens) &#124;                                                                                                                                                                                                                                                                                                                                            |\n|12 |Held, L., **Rufibach, K.**, Balabdaoui, F. (**2010**). A score regression approach to assess calibration of probabilistic predictions. _Biometrics_, **66**(4), 1295-1305.  [doi](http://dx.doi.org/10.1111/j.1541-0420.2010.01406.x) &#124;                                                                                                                                                                                                                                                                                                                                                                                                      |\n|11 |Balabdaoui, F., **Rufibach, K.**, Santambrogio, F. (**2010**). Least Squares estimation of two ordered monotone regression curves. _J. Nonparametr. Stat._, **22**(8), 1019-1037.  [doi](http://dx.doi.org/10.1080/10485250903548729) &#124;  [preprint](http://arxiv.org/abs/0904.2052) &#124;  [R package on cran](http://cran.r-project.org/package=OrdMonReg) &#124;                                                                                                                                                                                                                                                                          |\n|10 |**Rufibach, K.**, Walther, G. (**2010**). The block criterion for multiscale inference about a density  with applications to other multiscale problems. _J. Comput. Graph. Statist._, **19**(1), 175-190.  [doi](http://dx.doi.org/10.1198/jcgs.2009.07071) &#124;  [R package on cran](http://cran.r-project.org/package=modehunt) &#124;                                                                                                                                                                                                                                                                                                        |\n|9  |**Rufibach, K.** (**2010**). An Active Set Algorithm to Estimate Parameters in Generalized Linear Models with Ordered Predictors. _Comput. Statist. Data Anal._, **54**:1442-1456.  [doi](http://dx.doi.org/10.1016/j.csda.2010.01.014) &#124;  [preprint](http://arxiv.org/abs/0902.0240) &#124;  [R package on cran](http://cran.r-project.org/package=OrdFacReg) &#124;                                                                                                                                                                                                                                                                        |\n|8  |**Rufibach, K.** (**2009**). reporttools: R Functions to Generate LaTeX Tables of Descriptive Statistics. _Journal of Statistical Software, Code Snippets_, **31**(1), NA.  [doi](http://www.jstatsoft.org/v31/c01) &#124;  [R package on cran](http://cran.r-project.org/package=reporttools) &#124;                                                                                                                                                                                                                                                                                                                                             |\n|7  |Müller, S., **Rufibach, K.** (**2009**). Smooth tail index estimation. _J. Statist. Comput. Simulation_, **79**:1155-1167.  [doi](http://dx.doi.org/10.1080/00949650802142667) &#124;  [preprint](http://arxiv.org/abs/math/0612140) &#124;  [R package on cran](http://cran.r-project.org/package=smoothtail) &#124;                                                                                                                                                                                                                                                                                                                             |\n|6  |Balabdaoui, F., **Rufibach, K.**, Wellner, J.A. (**2009**). Limit distribution theory for maximum likelihood estimation of a log-concave density. _Ann. Statist._, **37**:1299-1331.  [doi](https://doi.org/10.1214/08-AOS609) &#124;  [preprint](http://arxiv.org/abs/0708.3400) &#124;  [R package on cran](http://cran.r-project.org/package=logcondens) &#124;                                                                                                                                                                                                                                                                                |\n|5  |Dümbgen, L., **Rufibach, K.** (**2009**). Maximum likelihood estimation of a log-concave density and its distribution function: basic properties and uniform consistency. _Bernoulli_, **15**:40-68.  [doi](http://dx.doi.org/10.3150/08-BEJ141) &#124;  [preprint](http://arxiv.org/abs/0709.0334) &#124;  [R package on cran](http://cran.r-project.org/package=logcondens) &#124;                                                                                                                                                                                                                                                              |\n|4  |Müller, S., **Rufibach, K.** (**2008**). On the max-domain of attraction of distributions with log-concave densities. _Statist. Probab. Lett._, **78**(12), 1440-1444.  [doi](http://dx.doi.org/10.1016/j.spl.2007.12.008) &#124;                                                                                                                                                                                                                                                                                                                                                                                                                 |\n|3  |Balabdaoui, F., **Rufibach, K.** (**2008**). A second Marshall inequality in convex estimation. _Statist. Probab. Lett._, **78**(2), 118-126.  [doi](http://dx.doi.org/10.1016/j.spl.2007.05.009) &#124;                                                                                                                                                                                                                                                                                                                                                                                                                                          |\n|2  |**Rufibach, K.** (**2007**). Computing Maximum Likelihood Estimators of a log-concave Density Function. _J. Stat. Comput. Simul._, **77**(7), 561-574.  [doi](http://dx.doi.org/10.1080/10629360600569097) &#124;  [R package on cran](http://cran.r-project.org/package=logcondens) &#124;                                                                                                                                                                                                                                                                                                                                                       |\n|1  |**Rufibach, K.**, Bertschy, M., Schüttel, M., Vock, M., Wasserfallen, T. (**2001**). Eintrittsraten und Austrittswahrscheinlichkeiten EVK 2000. _Mitteilungen der Schweizerischen Aktuarvereinigung_, **2001**(1), 49-70.  [doi](files/publications/001_2001_Rufibach et al, Eintrittsraten EVK.pdf) &#124;                                                                                                                                                                                                                                                                                                                                       |\n:::\n:::\n\n::: {.cell}\n\n:::\n\n# Invited discussions in statistical journals {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|   |                                                                                                                                                                                                                                                  |\n|:--|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|1  |Rufibach (**2010**). Proposal of the vote of thanks in discussion of Cule M. / Samworth R. and Stewart M.: Maximum likelihood estimation of a multidimensional logconcave density. _J. R. Stat. Soc. Ser. B Stat. Methodol._, **72**(5), 577-578. |\n:::\n:::\n\n::: {.cell}\n\n:::\n\n# Letters to the editor in Statistical Journals {-} \n\n::: {.cell}\n::: {.cell-output-display}\n|   |                                                                                                                                                                                                                                                                                                 |\n|:--|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|\n|2  |Hampson, L.V. and Degtyarev, E. and Tang, R., and Lin, J. and **Rufibach, K.** and Zheng, C. (**2023**). Biostatistical considerations when using RWD and RWE in clinical studies for regulatory purposes: A landscape assessment. _Statistics in Biopharmaceutical Research_, **15**(1), 23-26. |\n|1  |Dukes, O. and Van Lancker, K. and Bornkamp, B. and Heinzmann, D. and **Rufibach, K.** and Wolbers, M. (**2021**). On Identification of the Principal Stratum Effect in Patients Who Would Comply If Treated. _Statistics in Biopharmaceutical Research_, **13**(4), 511-512.                     |\n:::\n:::\n\n\n:::",
    "supporting": [],
    "filters": [
      "rmarkdown/pagebreak.lua"
    ],
    "includes": {},
    "engineDependencies": {},
    "preserve": {},
    "postProcess": true
  }
}